6 months ago
CRVO
AnalystsSumant KulkarniSumant Kulkarni's Stock Forecasts
AnalystsSumant Kulkarni
Analyst Ranking
Bottom 5%
#4795 out of 5017 analysts
Average Return
-5.1%
Win Rate
38%37 out of 97
Risk vs Reward
Poor
Good
Sumant Kulkarni's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cervomed IncCRVO | +337.95% | $1.95 | $8.54 | 2024-12-10 - 2025-09-15 | Strong Buy |
Atai Life Sciences NvATAI | +178.44% | $1.67 | $4.65 | 2024-11-17 - 2025-09-15 | Strong Buy |
Sage Therapeutics IncSAGE | +157.05% | $30.01 | $77.14 | 2020-04-07 - 2021-04-08 | Strong Buy |
Biohaven Pharmaceutical Holding Co LtdBHVN1 | +126.10% | $22.49 | $50.85 | 2018-03-26 - 2019-03-27 | Strong Buy |
Zevra Therapeutics IncZVRA | +102.70% | $4.44 | $9.00 | 2023-11-07 - 2024-11-08 | Strong Buy |
Sumant Kulkarni Analyst Color
Get additional color on Sumant Kulkarni's coverage of popular stocks
2 years ago
CYBN
2 years ago
SAGE
2 years ago
CYBN
Sumant Kulkarni's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Clene IncCLNN | 6 | Strong Buy | $48.00 | +668.00% | Maintains | a month ago |
Compass Pathways PLCCMPS | 4 | Strong Buy | $15.00 | +191.83% | Maintains | a month ago |
Cervomed IncCRVO | 6 | Strong Buy | $27.00 | +216.16% | Maintains | 2 months ago |
Atai Life Sciences NvATAI | 3 | Strong Buy | $11.00 | +136.56% | Maintains | 2 months ago |
Cybin IncCYBN | 8 | Strong Buy | $70.00 | +1,064.73% | Maintains | 2 months ago |
Sage Therapeutics IncSAGE | 7 | Hold | $8.50 | -2.07% | Maintains | 3 months ago |
Annovis Bio IncANVS | 3 | Strong Buy | $17.00 | +611.30% | Maintains | 4 months ago |
Neurocrine Biosciences IncNBIX | 10 | Strong Buy | $160.00 | +13.93% | Maintains | 4 months ago |
Biogen IncBIIB | 12 | Strong Buy | $220.00 | +53.50% | Maintains | 4 months ago |
Zevra Therapeutics IncZVRA | 7 | Strong Buy | $25.00 | +245.78% | Maintains | 6 months ago |
Voyager Therapeutics IncVYGR | 4 | Strong Buy | $12.00 | +185.04% | Maintains | 6 months ago |
Intra Cellular Therapies IncITCI | 5 | Hold | $132.00 | +0.10% | Downgrades | 8 months ago |
Bioxcel Therapeutics IncBTAI | 7 | Strong Buy | $80.00 | +2,423.66% | Maintains | 8 months ago |
Gh Research PLCGHRS | 4 | Strong Buy | $28.00 | +113.58% | Maintains | 10 months ago |
Mind Medicine IncMNMD | 1 | Strong Buy | $14.00 | +46.60% | Maintains | a year ago |
Tvardi Therapeutics IncTVRD | 4 | Hold | $12.00 | N/A | Downgrades | a year ago |
Stoke Therapeutics IncSTOK | 3 | Strong Buy | $20.00 | N/A | Maintains | a year ago |
Acadia Pharmaceuticals IncACAD | 7 | Strong Buy | $33.00 | N/A | Maintains | 2 years ago |
Zynerba Pharmaceuticals IncZYNE | 2 | Hold | $1.11 | N/A | Downgrades | 2 years ago |
Quince Therapeutics IncQNCX | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Biohaven Pharmaceutical Holding Co LtdBHVN1 | 3 | Strong Buy | $150.00 | N/A | Maintains | 4 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Strong Buy | $20.00 | N/A | Maintains | 7 years ago |
Avexis IncAVXS | 1 | Hold | $120.00 | N/A | Maintains | 8 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Strong Buy | N/A | N/A | Upgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.